RECRUITINGOBSERVATIONAL
Thyroid Dysfunction and Its Association With Metabolic Dysfunction-Associated Fatty Liver Disease
About This Trial
This study aims to evaluate the prevalence of thyroid dysfunction and its association with metabolic dysfunction-associated fatty liver disease.
Who May Be Eligible (Plain English)
Who May Qualify:
- Age ≥ 18 years.
- Both sexes.
- Patients with metabolic dysfunction-associated fatty liver disease (MAFLD).
Who Should NOT Join This Trial:
- History of thyroid disease or treatment (e.g., thyroid nodules, thyroid cancer, hypothyroidism, and hyperthyroidism).
- Patients with alcoholic liver disease take more than 40g of alcohol (or four units) per day.
- Viral hepatitis.
- Pregnant women.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Age ≥ 18 years.
* Both sexes.
* Patients with metabolic dysfunction-associated fatty liver disease (MAFLD).
Exclusion Criteria:
* History of thyroid disease or treatment (e.g., thyroid nodules, thyroid cancer, hypothyroidism, and hyperthyroidism).
* Patients with alcoholic liver disease take more than 40g of alcohol (or four units) per day.
* Viral hepatitis.
* Pregnant women.
Treatments Being Tested
DEVICE
Fibroscan
Fibroscan will be used to assess the stages of fibrosis and steatosis using Dimensional ultrasound TE (transient elastography). Dimensional ultrasound TE (transient elastography) will be used for staging liver fibrosis and steatosis by measuring the velocity of a low frequency (50 Hz) elastic shear wave propagating through the liver.
Locations (1)
Tanta University
Tanta, El-Gharbia, Egypt